Expression of CD11c and EMR2 on neutrophils: Potential diagnostic biomarkers for sepsis and systemic inflammation

TY - JOUR

T1 - Expression of CD11c and EMR2 on neutrophils

T2 - Potential diagnostic biomarkers for sepsis and systemic inflammation

AU - Lewis, Sion

AU - Treacher, David F

AU - Edgeworth, Jonathan

AU - Mahalingam, Gaia

AU - Brown, Carys S

AU - Mare, Tracey A

AU - Stacey, Martin

AU - Beale, Richard

AU - Brown, K Alun

N1 - © 2015 British Society for Immunology.

PY - 2015/7/7

Y1 - 2015/7/7

N2 - There is a need for cellular biomarkers to differentiate patients with sepsis from those with the non-infectious systemic inflammatory response syndrome (SIRS). In this double-blind study we determined whether the expression of known (CD11a/b/c, CD62L) and putative adhesion molecules (CD64, CD97 and EMR2) on blood neutrophils could serve as useful biomarkers of infection and of non-infectious SIRS in critically ill patients. We studied 103 patients with SIRS, 80 of whom had sepsis and 50 healthy normal subjects using flow cytometry to phenotypically characterise neutrophils in whole blood samples. Patients with SIRS had an increased prevalence of neutrophils expressing CD11c, CD64 and EMR2 in comparison with healthy subjects (p<0.001) but a normal expression of CD11a, CD11b, CD62L and CD97. An increase in the percentage of neutrophils bearing CD11c was associated with sepsis, EMR2 with SIRS and CD64 with sepsis and SIRS. Neutrophils expressing CD11c had the highest sensitivity (81%) and specificity (80%) for the detection of sepsis and there was an association between the percentage of neutrophils expressing EMR2 and the extent of organ failure (p<0.05). Contrary to other reports we did not observe an abnormal expression of CD11b or CD62L on neutrophils from patients with SIRS and suggest that this discrepancy is due to differences in cell processing protocols. We propose that blood neutrophils expressing CD11c and EMR2 be considered as potential biomarkers for sepsis and SIRS respectively.

AB - There is a need for cellular biomarkers to differentiate patients with sepsis from those with the non-infectious systemic inflammatory response syndrome (SIRS). In this double-blind study we determined whether the expression of known (CD11a/b/c, CD62L) and putative adhesion molecules (CD64, CD97 and EMR2) on blood neutrophils could serve as useful biomarkers of infection and of non-infectious SIRS in critically ill patients. We studied 103 patients with SIRS, 80 of whom had sepsis and 50 healthy normal subjects using flow cytometry to phenotypically characterise neutrophils in whole blood samples. Patients with SIRS had an increased prevalence of neutrophils expressing CD11c, CD64 and EMR2 in comparison with healthy subjects (p<0.001) but a normal expression of CD11a, CD11b, CD62L and CD97. An increase in the percentage of neutrophils bearing CD11c was associated with sepsis, EMR2 with SIRS and CD64 with sepsis and SIRS. Neutrophils expressing CD11c had the highest sensitivity (81%) and specificity (80%) for the detection of sepsis and there was an association between the percentage of neutrophils expressing EMR2 and the extent of organ failure (p<0.05). Contrary to other reports we did not observe an abnormal expression of CD11b or CD62L on neutrophils from patients with SIRS and suggest that this discrepancy is due to differences in cell processing protocols. We propose that blood neutrophils expressing CD11c and EMR2 be considered as potential biomarkers for sepsis and SIRS respectively.

U2 - 10.1111/cei.12679

DO - 10.1111/cei.12679

M3 - Article

C2 - 26153037

SN - 1365-2249

JO - Clinical and Experimental Immunology

JF - Clinical and Experimental Immunology

ER -